<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05052424</url>
  </required_header>
  <id_info>
    <org_study_id>21-1384</org_study_id>
    <nct_id>NCT05052424</nct_id>
  </id_info>
  <brief_title>Immun Response in Children With MIS-C</brief_title>
  <official_title>Cellular and Molecular Characterization of the Immune Response in Children and Adolescents With Inflammatory Syndrome in Children (MIS-C)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cologne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Cologne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multi-system inflammatory syndrome in children (MIS-C) is a post-viral inflammatory&#xD;
      vasculopathy of children and adolescents following Covid-19 infection. It affects one of&#xD;
      1000-5000 children. Latency between mild or asymptomatic Covid-19 infection and MIS-C is 4-6&#xD;
      weeks. The immune response in MIS-C seems to be dysregulated and different from that during&#xD;
      acute SARS-CoV-2 infection.&#xD;
&#xD;
      The investigators are planning to investigate the immune response in children with MIS-C.&#xD;
&#xD;
      RNA and protein expression of cytokines and immune cell-related markers will be determined&#xD;
      via multiplex ELISA, FACS, quantitative PCR, RNAseq, and Western blot.&#xD;
&#xD;
      The use of highly sensitive multiplex methods will allow for the analysis of a large number&#xD;
      of parameters in the smallest possible amount of sample. Sample preparation and analysis will&#xD;
      be performed in close collaboration with the Centre for Molecular Medicine Cologne (CMMC) and&#xD;
      the Institute of Virology.&#xD;
&#xD;
      With this project the investigators hope to identify risk factors for developing MIS-C and&#xD;
      extend the knowledge on therapeutic options for the treatment of this condition.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Immune response in MIS-C</measure>
    <time_frame>December 2022</time_frame>
    <description>.The primary outcome measure is a complex pattern of numerous molecular markers of immune response determined via multiplex ELISA, FACS, quantitative PCR, RNAseq. and Western Blot. For each child, this specific molecular immune response pattern will be determined and correlated with clinical determinants allowing for the identification of predictive factors and molecular markers useful for the management of future patients.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>MIS-C Multisystem Inflammatory Syndrome in Children</condition>
  <arm_group>
    <arm_group_label>Children with MIS-C</arm_group_label>
    <description>Children (age &lt;18 years) hospitalized in the Children´s University Hospital of Cologne diagnosed with MIS-C (WHO criteria)&#xD;
Assessment of clinical data&#xD;
Blood samples are taken before therapy and on days 1,2,5,7 und 9.&#xD;
RNA and protein expression of cytokines and immune cell-related markers will be determined via multiplex ELISA, FACS, quantitative PCR, RNAseq, and Western blot.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Analysis of cytokines and immun cell related markers</intervention_name>
    <description>blood samples</description>
    <arm_group_label>Children with MIS-C</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood sample&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Children with MIS-C&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosed with MIS-C (WHO criteria)&#xD;
&#xD;
          -  &lt;18 years&#xD;
&#xD;
          -  Hospitalized in the Children´s University Hospital of Cologne&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  no informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Katrin Mehler, MD</last_name>
    <phone>0049221478</phone>
    <phone_ext>5998</phone_ext>
    <email>Katrin.Mehler@uk-koeln.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andre Oberthuer, MD</last_name>
    <phone>0049221478</phone>
    <phone_ext>4449</phone_ext>
    <email>Andre.Oberthuer@uk-koeln.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Cologne, Medical Faculty</name>
      <address>
        <city>Cologne</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 31, 2021</study_first_submitted>
  <study_first_submitted_qc>September 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 22, 2021</study_first_posted>
  <last_update_submitted>September 13, 2021</last_update_submitted>
  <last_update_submitted_qc>September 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cologne</investigator_affiliation>
    <investigator_full_name>Katrin Mehler</investigator_full_name>
    <investigator_title>PD Dr. Katrin Mehler, Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

